A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio, Inc
Atavistik Bio, Inc
K36 Therapeutics, Inc.
Alterome Therapeutics, Inc.
M.D. Anderson Cancer Center
Elevation Oncology
University of Pittsburgh
Plus Therapeutics
Engeneic Pty Limited
Revolution Medicines, Inc.
Endocyte
Poseida Therapeutics, Inc.
Blueprint Medicines Corporation
Blueprint Medicines Corporation
Revolution Medicines, Inc.
Advaxis, Inc.
Aragon Pharmaceuticals, Inc.
Blueprint Medicines Corporation
Revolution Medicines, Inc.
The Methodist Hospital Research Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
H. Lee Moffitt Cancer Center and Research Institute
VA Office of Research and Development
Bristol-Myers Squibb
AVEO Pharmaceuticals, Inc.
Pharmacyclics LLC.